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OBJECTIVES The goal of this study was to determine the bioactivity of urocortin (Ucn) in experimental
heart failure (HF).
BACKGROUND Urocortin may participate in cardiovascular function and pressure/volume homeostasis. Its
effects in HF are unknown.
METHODS Eight normal sheep and eight sheep with pacing-induced HF received ovine Ucn (10, 50, and
100 mg intravenous boluses at 2-h intervals) in vehicle-controlled studies.
RESULTS Urocortin boluses dose-dependently increased plasma Ucn (p  0.001). Pharmacokinetics
were similar in normal and HF sheep with half-lives approximating 1.3 and 19.5 h for the first
and second phases, respectively. In HF, cardiac output increased (twofold), while peripheral
resistance, left atrial pressure (both 50% falls: p  0.001), and mean arterial pressure (p 
0.05) fell. In normal sheep, changes in peripheral resistance and atrial pressure were blunted
and in arterial pressure were directionally opposite. Urocortin induced persistent, dose-
dependent falls (30% to 50%) in plasma vasopressin, renin activity, aldosterone, natriuretic
peptides (all p  0.001), and endothelin-1 (p  0.05) in HF sheep, while adrenocorticotro-
phic hormone and cortisol levels rose acutely (both p 0.001). In comparison, Ucn in normal
sheep resulted in a similar rise in cortisol and fall in aldosterone, no significant effects on
plasma renin activity and natriuretic peptides, and a rise in vasopressin. Urocortin produced
dose-dependent, sustained increases in urine volume (twofold, p  0.01), sodium excretion
(9-fold rise, p  0.001), and creatinine clearance (p  0.001) in HF sheep. No significant
renal effects were observed in normal sheep.
CONCLUSIONS Urocortin has profound and sustained hemodynamic, hormonal, and renal effects in
experimental HF. Urocortin may have a role in pressure/volume homeostasis in HF and may
provide a novel therapeutic approach to this disease. (J Am Coll Cardiol 2002;40:
1495–505) © 2002 by the American College of Cardiology Foundation
Urocortin (Ucn), a recently isolated 40-amino acid peptide
member of the corticotropin-releasing factor (CRF) family
(1), may play a role in cardiovascular and volume homeosta-
sis. Originally identified in rat midbrain (1), Ucn has
subsequently been detected in the heart, brain, vasculature,
kidney, and digestive system (2–6). The distribution of
Ucn’s proposed endogenous receptor, CRF-R2 (7,8), func-
tionally linked to adenylate cyclase, overlaps with that of
Ucn in both the central nervous system and periphery
(2,3,8,9). In the rat, cerebral Ucn immunoreactivity is
increased by dehydration (10) and salt loading (11), while
cardiac Ucn messenger RNA expression is raised in left
ventricular (LV) hypertrophy (2) and in cardiac myocytes
after ischemia (12). In humans, immunoreactivity is in-
creased in the ventricles of patients with dilated cardiomy-
opathy (2).
A number of actions have been attributed to Ucn. It
stimulates secretion of adrenocorticotrophic hormone
(ACTH) from isolated rat pituitary cells (1), and atrial and
brain natriuretic peptide (ANP and BNP) from rat cardiac
myocytes (13). Central administration of Ucn attenuates
hyperosmolality-induced arginine vasopressin (AVP) release
in the rat (14), and subcutaneous Ucn inhibits
lipopolysaccharide-induced serum tumor necrosis factor in
mice (15). Urocortin is also reported to protect cardiac
myocytes from cell death induced by hypoxia (16) and
reduce damage in isolated rat hearts subjected to regional
ischemia/reperfusion (17). Hemodynamic effects of periph-
erally administered Ucn include vasodilation in the rat (1)
and increases in cardiac contractility, coronary blood flow
and conductance, cardiac output, and heart rate (HR) in
normal sheep (18).
In view of the potential roles that Ucn may play in
cardiovascular/volume homeostasis and the pathophysiology
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of heart failure (HF), we have conducted the first controlled
studies of the integrated hemodynamic, endocrine, and
renal effects of Ucn in experimental HF.
METHODS
Surgical preparation. A total of 16 Coopworth ewes (43 to
55 kg) were instrumented under general anesthesia (induced
by 17 mg/kg thiopentone; maintained with halothane/
nitrous oxide). In eight sheep (normal group) a carotid
artery was cannulated (16 G Angiocath) for direct measure-
ment of mean arterial pressure (MAP) and HR, and a
polyethylene catheter was placed in the jugular vein for
recording of right atrial pressure (RAP) and blood sampling.
A Swan-Ganz thermodilution catheter (American Ed-
wards, Irvine, California) was placed in the pulmonary
artery via the jugular vein for the measurement of cardiac
output (CO).
The other eight sheep (HF group) were instrumented via
a left lateral thoracotomy (19). Two polyvinyl chloride
catheters were inserted in the left atrium for blood sampling
and left atrial pressure (LAP) determination; a Konigsberg
pressure-tip transducer was inserted in the aorta to record
MAP; an electromagnetic flow probe was placed around the
ascending aorta to measure CO, and a 7F His-bundle
electrode was stitched subepicardially to the wall of the LV
for LV pacing.
In both groups a bladder catheter was inserted for urine
collections. Animals recovered for 7 (normals) or 14 days
(HF) before studies commenced. During experiments, the
animals, held in metabolic cages, had free access to water
and food (containing 80 mmol/day sodium; 200 mmol/day
potassium).
Study protocol. Heart failure was induced by seven days of
rapid LV pacing (225 beats/min) (19). Pacing was contin-
ued throughout the study period. In both groups, each sheep
received intravenous boluses of ovine Ucn (10, 50, and 100
mg at 2-h intervals) (American Peptide Company, Sunny-
vale, California) or a vehicle control (10 ml 0.9% saline)
administered two days apart in a balanced random order.
Mean arterial pressure, RAP/LAP, CO, and calculated
total peripheral resistance (CTPR  MAP/CO) were
recorded at 15-min intervals in the hour preceding the first
bolus at 10:00 AM (baseline); at 15, 30, 45, 60, 90, and 120
min succeeding each bolus; and at 10:00 AM the following
day. Hemodynamic measurements were determined by
online computer-assisted analysis using established methods
(20,21).
Blood samples (25 ml) were drawn from the jugular vein
(normal group) or left atrium (HF group) at 30 min; and
immediately preceding the first bolus at 10:00 AM (baseline);
at 30, 60, and 120 min succeeding each bolus; and at 10:00
AM the following day. Samples were taken into tubes on ice,
centrifuged at 4°C, and stored at either 20°C or 80°C
before assay for immunoreactive Ucn, cyclic adenosine
monophosphate (cAMP), AVP, ACTH, cortisol,
endothelin-1, plasma renin activity (PRA), angiotensin II
(AngII-HF sheep only), aldosterone, ANP, BNP, and
catecholamines (19–22). All samples of each hormone from
individual animals were measured in the same assay to avoid
inter-assay variability. Plasma electrolytes, glucose, and
hematocrit were measured with every blood sample taken.
Plasma Ucn concentrations were determined via radio-
immunoassay. The samples initially underwent methanol
extraction where 1 ml plasma was mixed with 2 ml meth-
anol (100%), centrifuged to remove precipitated proteins,
and the supernatant dried down and reconstituted in 0.5 ml
assay buffer. One hundred microliters of the extract or rat
Ucn standard (Bachem, Torrance, California) were then
incubated with 100 l anti-serum (raised in rabbit to rat
Ucn [identical to ovine Ucn] [23] coupled to human
-globulins [2.5 mg/ml serum] via glutaraldehyde [The
Salk Institute, La Jolla, California]) and 100 l radiolabeled
(I125) rat Ucn. Bound and free labeled Ucn were separated
using a solid phase second antibody. Recovery of unlabeled
Ucn standard was 65% to 75%. The detection limit of the
assay was 3.8 pmol/l, and the IC50 was 90.4 pmol/l.
Intra-assay coefficients of variation (CV) were 7.7% and
6.2% over the ranges of 0 to 100 and 100 to 250 pmol/l,
respectively, and inter-assay CVs were 14.1% and 11.9% at
30 and 80 pmol/l, respectively. Cross reactivity to ovine
CRF (American Peptide Company), human CRF (Penin-
sula Laboratories, San Carlos, California), and human
urotensin II (Phoenix Pharmaceuticals, Belmont, Califor-
nia) was 0.001% and to murine Ucn-II was 0.026%.
Urocortin plasma half-life, clearance, and volume of
distribution were calculated using a two-compartment
model (WinNonLin Professional 3.1, Pharsight Corpora-
tion, Mountain View, California).
Urine volume and samples for the measurement of urine
cAMP, sodium, potassium, and creatinine excretion were
collected at two hourly intervals before (baseline) and after
each bolus and overnight (4:00 PM to 10:00 AM).
Abbreviations and Acronyms
ACTH  adrenocorticotrophic hormone
AngII  angiotensin II
ANP  atrial natriuretic peptide
AVP  arginine vasopressin
BNP  brain natriuretic peptide
cAMP  cyclic adenosine monophosphate
CO  cardiac output
CRF  corticotropin-releasing hormone
CTPR  calculated total peripheral resistance
CV  coefficients of variation
HF  heart failure
HR  heart rate
LAP  left atrial pressure
LV  left ventricle/ventricular
MAP  mean arterial pressure
PRA  plasma renin activity
RAP  right atrial pressure
Ucn  urocortin
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The study protocol was approved by the local Animal
Ethics Committee.
Statistics. Results are expressed as mean  SEM. To test
for baseline differences between normal and HF sheep,
baseline data from each state (mean of measurements made
within the hour before treatment) were compared using
paired t tests. To test for the effects of Ucn, control and Ucn
study limbs (in both normal and HF sheep separately) were
compared using repeated measures analysis of variance
(ANOVA). Where significant differences were noted, the
level of significance at individual time points on figures and
tables was determined using pairwise least-significant-
difference tests with the appropriate mean-square error term
from the ANOVA (Fisher protected least-significant-
difference test). To test for differences in the response to Ucn
between normal and HF states, Ucn study limbs in each state
were compared by covariate ANOVA using baseline data as
the covariates. Significance was assumed at p  0.05.
RESULTS
Pacing induced the hemodynamic, hormonal, and sodium
retaining hallmarks of congestive HF, with significantly
reduced MAP and CO and increased LAP and hormone
levels (Figs. 1 to 5).
Hemodynamics. In HF, Ucn doubled CO and halved
CTPR and LAP (all p  0.001), restoring these indexes
toward normal levels. These effects were still evident at 24 h
(Fig. 1). Reductions in MAP were small (p  0.05) and not
dose-dependent. Hematocrit was elevated the day after Ucn
administration (p  0.05) (Table 1).
In normal sheep, Ucn also increased CO (p 0.001), but
downward trends in CTPR and atrial pressures were not
significant. In contrast with HF sheep, Ucn increased MAP
(p  0.001). Heart rate (fixed at 225 beats/min in the HF
group) increased twofold with Ucn (p  0.001) in normal
sheep and remained elevated at 24 h (Table 1).
Figure 1. Mean  SEM hemodynamic responses to incremental boluses of urocortin and a vehicle control in eight normal sheep (left panel) and eight
heart failure sheep (right panel). Baseline data points represent the mean of four samples taken in the hour preceding treatment. Significant differences
(compared with time-matched control) are shown by: *p  0.05; **p  0.01; †p  0.001.
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Comparing HF and normal groups, CTPR and atrial
pressures fell more in HF sheep (both p  0.001), and
effects on MAP were directionally opposite (p  0.001).
Hormones. In HF sheep, Ucn dose-dependently increased
plasma Ucn (p  0.001) from 20  2 to 336  45, 1,900
 143, and 4,836  355 pmol/l, respectively, 30 min after
each bolus (Fig. 2). Concentrations remained elevated at
24 h (1,405  239 pmol/l). Urocortin plasma half-life was
calculated as 1.23 0.60 and 20.1 3.35 h for the first and
second phases, respectively, clearance as 0.43  0.06 and
3.09 0.86 l/h, and volume of distribution as 10.05 1.05
and 5.39  0.72 l. Urocortin substantially and dose-
dependently reduced plasma AVP (p  0.001), PRA (p 
0.001), aldosterone (p  0.001), ET-1 (p  0.05), AngII
(p  0.001), ANP (p  0.001), and BNP (p  0.001)
concentrations (Figs. 2 to 4, Table 1). These factors were
still decreased relative to control at 10:00 AM the follow-
ing day. Conversely, Ucn induced acute rises in plasma
ACTH (p  0.001) and cortisol (p  0.001) (Fig. 2) that
were not dose-related. Circulating cAMP (Table 1) and
catecholamine levels (Fig. 4) were unchanged compared
with control.
In normal sheep, plasma Ucn levels and pharmacokinetics
were similar to those in HF. Plasma Ucn increased from
12.3  1.3 to 219  19; 1,777  91; and 4,142  175
pmol/l, respectively, 30 min after each bolus (p  0.001).
Plasma half-life was calculated as 1.32  0.39 and 19.1 
1.96 h for the first and second phases, respectively, clearance
as 0.38  0.05 and 2.18  0.71 l/h, and volume of
distribution as 9.44  0.41 and 3.40  0.48 l. Compared
with control, Ucn in normals increased plasma AVP (p 
0.05) and cortisol levels (p  0.001), reduced plasma
aldosterone (p  0.05) and ET-1 levels (p  0.05), but had
no significant effects on PRA, plasma ACTH, ANP, BNP,
catecholamines (Figs. 2 to 4), or cAMP levels (Table 1).
Comparison between groups showed significantly differ-
ent effects on PRA (p 0.01), ANP (p 0.001), and BNP
(p  0.001), which all fell in HF sheep but did not change
Figure 2. Mean  SEM plasma urocortin, arginine vasopressin, adrenocorticotrophic hormone (ACTH), and cortisol responses to incremental boluses of
urocortin and a vehicle control in eight normal sheep (left panel) and eight heart failure sheep (right panel). Significant differences are shown by: *p 0.05;
**p  0.01; †p  0.001.
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significantly in normal sheep, and directionally opposite
effects on plasma AVP (p 0.001). Second phase volume of
distribution was greater in HF sheep (p  0.05).
Urine and plasma electrolytes. In HF sheep, Ucn dose-
dependently increased urine volume (twofold, p  0.01),
sodium (ninefold, p  0.001), creatinine (p  0.001) and
cAMP excretion (p  0.01) (Fig. 5), and creatinine clear-
ance (p  0.001) (Table 1). These variables remained
elevated above controls at 24 h. Potassium excretion rose
after Ucn (p  0.05). Water intake was unaltered (Table 1).
Urocortin reduced plasma potassium (p  0.001) and
creatinine (p  0.01) concentrations and increased plasma
glucose (p  0.001)—the latter two responses still apparent
at 24 h (Table 2). Urocortin did not significantly affect
plasma sodium concentrations.
In normal sheep there was no significant effect on any of
the urinary parameters measured (Fig. 5, Table 1). Urocor-
tin reduced plasma potassium (p  0.05) and increased
plasma glucose (p  0.001) but had no effect on water
intake, plasma sodium, or creatinine levels (Tables 1 and 2).
Comparison between HF and normal groups showed
significantly greater effects of Ucn on sodium and potassium
excretion (both p  0.05) and urinary volume (p  0.01) in
HF sheep.
DISCUSSION
This is the first report of the hemodynamic, hormonal, and
renal effects of acute intravenous Ucn in experimental HF.
In HF, Ucn induced profound reductions in CTPR and
ventricular filling pressures, and increases in cardiac output
in concert with broad spectrum falls in neurohormonal
activation (including inhibition of the renin-angiotensin-
aldosterone axis and the vasoconstrictor peptides AVP and
ET-1) and pronounced augmentation of renal function.
Responses to Ucn in HF sheep—especially MAP, CTPR,
atrial pressures, PRA, plasma AVP, ANP and BNP, and
renal indexes—differed markedly from those found in
normal sheep. This combination of sustained responses
incorporates many of the therapeutic goals of HF manage-
ment where this peptide or similarly acting compounds may
ultimately have clinical applications in human HF.
Figure 3. Mean  SEM plasma renin activity, aldosterone, and endothelin-1 responses to incremental boluses of urocortin and a vehicle control in eight
normal sheep (left panel) and eight heart failure sheep (right panel). Significant differences are shown by: *p  0.05; **p  0.01; †p  0.001.
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Hemodynamics. Urocortin induced prompt (15 min) and
impressive dose-dependent rises in CO in HF. In keeping
with the residual levels of Ucn in plasma, CO was still
significantly elevated 20 h after the bolus. Similar observa-
tions of marked and sustained CO responses were seen in
the normal sheep and have been previously reported by
Parkes et al. (18). While this effect in HF must at least
partially reflect a reduction in cardiac afterload, the previ-
ously reported potent positive inotropic actions of Ucn (24)
may also play a role. Indeed, inotropic activity is suggested
in the present study by marked increments in CO in the face
of profound falls in filling pressure (especially as changes in
MAP were modest relative to the marked increase in CO
and steep fall in CTPR). As with any inotropic agent, there
is a potential concern of pro-arrhythmic activity with Ucn.
While there have been no reports of pro-arrhythmic effects
of either CRF or Ucn, nor has our experience with Ucn in
normal or paced sheep (where it is possible that the stress of
rapid pacing plus a pro-arrhythmic agent might cause
ventricular tachycardia/fibrillation, seen as escape from pac-
ing) indicated any such activity, this possible side effect
requires further investigation.
The moderate blood pressure-lowering effects of Ucn in
sheep with HF contrasted with the pressor effect we
observed in normal sheep as was reported previously by
Parkes et al. (18). The difference in MAP responses be-
tween HF and normal animals may be due, in part, to the
preconstricted state of the arterial vasculature in HF. The
hypotensive effect—at least at higher doses of Ucn—in the
HF sheep may be mediated to some extent by its actions to
substantially reduce elevated plasma levels of the potent
vasoconstrictor peptides AngII, endothelin-1, and AVP.
Urocortin also induced striking dose-dependent and per-
sistent reductions in LAP in the HF sheep, presumably a
consequence of the large increases in CO, although a
possible contribution from reduced venous tone cannot be
excluded from our data. A decrease in circulating volume is
unlikely to have contributed acutely, although this may have
been a contributing factor the following day (when preload
was still significantly reduced) as judged by the vigorous
Figure 4. Mean  SEM plasma atrial natriuretic peptide, brain natriuretic peptide, norepinephrine, and epinephrine responses to incremental boluses of
urocortin and a vehicle control in eight normal sheep (left panel) and eight heart failure sheep (right panel). Significant differences are shown by: *p 0.05;
†p  0.001.
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natriuresis/diuresis sustained overnight and the rise in he-
matocrit. The minor decline in MAP in concert with major
falls in LAP and CTPR and increments in CO can be seen
as a desirable hemodynamic profile in HF—with enhanced
tissue blood flow coupled with sustained perfusion pressure.
This pattern contrasts with current standard treatment with
angiotensin-converting enzyme inhibition, which can in-
duce profound falls in systemic pressure (with concomitant
risks of impaired cerebral and renal perfusion) and only
modest increments in CO.
Urocortin significantly increased HR in normal sheep,
confirming the positive chronotropic effects of this peptide
previously reported (18). It was not possible to assess
changes in HR in the HF sheep as the pacemaker must
remain on at 225 beats/min throughout the study period to
maintain the stable HF profile. This represents a drawback
of the pacing-induced model of HF. Thus, the effects of
Ucn on HR in HF remain to be determined.
Hormones. Baseline plasma Ucn levels tended to be ele-
vated in these sheep with HF (20  2 pmol/l) compared
with normal animals (12.3  1.3 pmol/l, p  NS).
Although Ucn has been detected in a wide variety of tissues
(2–6), the source of circulating Ucn is unknown (in either
physiological or pathophysiological conditions). It is possi-
ble, however, that there may be some cardiac contribution to
the raised plasma levels of the peptide observed in this
model of HF, given the augmented Ucn immunoreactivity
and gene expression demonstrated in the cardiac ventricles
of animals and patients with heart disease (2). Cytokines
(interleukins-1 and -6, tumor necrosis factor-) (25) and
ischemia (12), both of which have been shown to stimulate
Ucn secretion from rat cardiomyocytes, may play a regula-
Figure 5. Mean  SEM urine volume, sodium, potassium, creatinine, and cyclic adenosine monophosphate (AMP) excretion in response to incremental
boluses of urocortin (striped bars) and a vehicle control (open bars) in eight normal sheep (left panel) and eight heart failure sheep (right panel). The
overnight sample was collected from 4:00 PM to 10:00 AM. Significant differences are shown by: *p  0.05; **p  0.01; †p  0.001.
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tory role in this setting. To our knowledge, only a single
study has previously measured Ucn in plasma (26), reporting
concentrations of approximately 15 pg/ml (3.2 pmol/l) in
normal humans. It remains to be seen whether plasma Ucn
levels are elevated in human HF. The current study docu-
ments for the first time the pharmacokinetics of Ucn, which
were similar in normal and HF sheep. Half-lives for first
and second phases were approximately 1.3 and 19.5 h,
respectively. The pharmacokinetics of Ucn in humans re-
main unknown. Despite marked increases in plasma Ucn,
plasma levels of cAMP, a proposed second messenger (8),
remained unchanged, and any response in urine cAMP was
inconsistent. However, significant hemodynamic and hor-
monal effects were observed within 15 to 30 min after the
lowest dose bolus, indicating Ucn is a rapidly acting hor-
mone. It is possible that Ucn stimulated cAMP sufficiently
at the tissue level to induce a biological response but
insufficiently to induce a measurable rise in circulating
concentrations. There is, however, evidence that alternative
pathways for Ucn exist, for example, via prostaglandin
generation (24).
Despite falls in arterial pressure (and plasma concentra-
tions of AVP and the natriuretic peptides) in the HF sheep,
PRA (and AngII) was dose-dependently reduced by Ucn.
Whether this was due to direct inhibition of renin release
from the juxtaglomerulus by Ucn, increased delivery of
sodium (and chloride) to the macula densa (reflected in the
significant rise in sodium excretion), or some other PRA-
inhibitory mechanism, remains to be seen. Trends for PRA
to fall in normal sheep were not significant in the current
study but have been reported previously (18). Aldosterone
concentrations were also reduced (more apparent in HF
sheep), presumably as a result of the decline in circulating
AngII (and perhaps plasma potassium) and notwithstanding
the substantial rise in ACTH. However, a direct effect of
Ucn on the adrenal glomerulosa cannot be excluded from
Table 1. Biological Effects of Incremental Intravenous Boluses of Ucn in Eight Normal Sheep
and Eight Sheep With HF
Baseline
10 mg Ucn 50 mg Ucn 100 mg Ucn
2 h 4 h 6 h 24 h
Hematocrit (%)
Normal
Control 32.5  1.1 31.3  0.8 31.3  0.8 29.8  0.8 29.6  0.7
Ucn 31.2  1.2 30.9  1.2 30.6  1.0 30.4  1.4 29.3  1.8
HF
Control 25.9  0.7 24.8  0.7 24.2  0.7 23.4  0.7 23.5  0.7
Ucn 26.0  0.8 24.4  0.7 23.9  0.7 23.4  0.9 25.2  0.9†
Heart rate (beats/min)
Normal
Control 92.8  7.6 85.0  7.4 91.0  8.4 87.0  6.7 92.0  3.8
Ucn 80.1  3.3 90.0  5.2 123.5  8.2† 153.5  12.6† 125.0  6.3†
Plasma angiotensin II (pmol/l)
HF
Control 47.6  9.5 48.3  11.7 52.3  15.2 54.3  12.5 65.9  11.6
Ucn 57.4  17.6 39.0  11.0 22.4  4.2† 20.1  2.6† 25.6  2.8†
Plasma cAMP (nmol/l)
Normal
Control 21.4  2.1 21.5  2.1 18.3  2.2 17.2  1.6 19.7  1.9
Ucn 19.8  1.5 18.8  1.4 16.7  1.1 19.6  1.7 21.3  2.2
HF
Control 34.3  2.5 30.9  2.5 30.4  2.5 33.0  3.4 37.3  6.4
Ucn 32.3  2.6 27.9  3.0 28.9  2.8 32.8  3.3 51.4  15.4
Creatinine clearance (ml/min)
Normal
Control 120  8 122  9 122  10 126  6 121  9
Ucn 122  10 122  8 124  9 128  10 129  7
HF
Control 89  7 90  7 81  6 79  6 80  7
Ucn 84  9 98  6* 106  6† 108  6† 103  5†
Water intake (ml/h)
Normal
Control 119  36 175  86 238  119 207  125 220  45
Ucn 146  21 125  65 63  26 82  40 183  43
HF
Control 192  70 158  46 65  32 127  60 58  10
Ucn 168  62 197  59 101  43 113  72 79  19
Values are mean  SEM. Significant differences (compared with time-matched control) are shown by: *p  0.05; †p  0.001.
cAMP  cyclic adenosine monophosphate; HF  heart failure; Ucn  urocortin.
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our data. The present study reports for the first time that
Ucn dose-dependently decreases plasma endothelin-1 con-
centrations—an effect even more apparent 20 h after bolus
in HF sheep. Such a response has not been observed by the
authors previously following administration of other vaso-
dilator peptides such as ANP/BNP or adrenomedullin
(unpublished data).
Urocortin induced stepped reductions in plasma ANP
and BNP levels in HF sheep. This is likely to reflect reduced
cardiac transmural pressures (as judged by the falls in LAP
and MAP) leading to reduced stimulus to secretion because
Ucn is reported to augment natriuretic peptide secretion
from rat cardiac myocytes (2,13). Our findings are in accord
with previous studies demonstrating a close parallelism
between falls in atrial pressures and plasma natriuretic
peptide levels with administration of vasodilator agents in
HF (22). Circulating ANP and BNP were still reduced
compared with control the following day—consistent with
the sustained reduction in LAP.
In contrast with effects observed in normal sheep, intra-
venous Ucn dose-dependently and persistently reduced
plasma AVP levels in sheep with HF. While it is possible
that circulating Ucn could affect AVP secretion/release via
neural connections that exist between the circumventricular
organs (e.g., lamina terminalis, subfornical organ) and
hypothalamic paraventricular and supraoptic nuclei, as well
as between the median eminence and posterior pituitary, it
is more likely that the changes in plasma AVP in HF relate
to improved CO and pressure to sinoaortic volume recep-
tors, and possibly to reductions in plasma AngII levels (27).
These data, together with evidence of Ucn suppression of
water intake (28), and upregulation of Ucn immunoreactiv-
ity in the supraoptic nucleus after dehydration (10) and in
the hypothalamo-neurohypophysial system after salt loading
(11), indicate this peptide is likely to be involved in blood
volume regulation, at least under some circumstances.
Plasma ACTH and cortisol levels rose acutely after each
Ucn bolus in HF sheep (not dose-related), suggesting a
direct stimulatory effect of Ucn on ACTH release from the
pituitary. It is likely that negative feedback of cortisol at the
pituitary level dampened the ACTH responses to subse-
quent doses of Ucn. Urocortin has previously been shown to
augment ACTH release from isolated rat pituitary cells and
in vivo in conscious rats (1) and sheep (18). The increases in
plasma cortisol observed in normal sheep confirm previous
findings (18). As demonstrated in rats after central admin-
istration (29), intravenous Ucn in the present study in-
creased plasma glucose concentrations in both normal and
HF sheep. It is conceivable that the elevation in plasma
cortisol may have contributed to this rise (through actions to
Table 2. Effects of Incremental Intravenous Boluses of Ucn on Plasma Electrolytes in Eight Normal Sheep and Eight Sheep With HF
Baseline
10 mg Ucn 50 mg Ucn 100 mg Ucn
2 h 4 h 6 h 24 h
Plasma sodium (mmol/l)
Normal
Control 146  0.6 145  0.6 145  0.5 145  0.6 145  0.5
Ucn 146  0.4 146  0.6 146  0.8 146  0.7 146  0.8
HF
Control 146  1.0 145  0.9 145  0.9 145  0.7 145  1.1
Ucn 146  1.2 146  1.0 145  0.6 145  0.6 146  0.6
Plasma potassium (mmol/l)
Normal
Control 4.2  0.1 4.1  0.1 4.1  0.1 4.4  0.4 4.0  0.1
Ucn 4.0  0.1 4.0  0.1 3.6  0.1* 3.5  0.1‡ 3.6  0.1*
HF
Control 4.0  0.2 4.0  0.2 4.1  0.2 4.1  0.2 4.0  0.2
Ucn 4.1  0.2 4.1  0.2 3.7  0.1† 3.6  0.1‡ 4.2  0.1
Plasma creatinine (mmol/l)
Normal
Control 0.077  0.004 0.078  0.005 0.073  0.005 0.071  0.004 0.074  0.006
Ucn 0.075  0.004 0.074  0.004 0.071  0.004 0.070  0.004 0.069  0.004
HF
Control 0.077  0.008 0.073  0.007 0.077  0.008 0.077  0.008 0.077  0.007
Ucn 0.077  0.007 0.076  0.006 0.073  0.006 0.071  0.005* 0.067  0.004‡
Plasma glucose (mmol/l)
Normal
Control 3.7  0.1 3.9  0.4 3.3  0.2 3.2  0.2 3.3  0.1
Ucn 3.7  0.1 3.8  0.1 4.1  0.2‡ 4.5  0.3‡ 4.1  0.2‡
HF
Control 3.7  0.1 3.7  0.2 3.7  0.2 3.6  0.1 3.4  0.1
Ucn 3.6  0.2 3.7  0.2 3.9  0.2 3.8  0.2* 4.0  0.1‡
Values are mean  SEM. Significant differences (compared with time-matched control) are shown by: *p  0.05; †p  0.01; ‡p  0.001.
HF  heart failure; Ucn  urocortin.
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increase glycogen storage, stimulate gluconeogenesis, and
reduce cellular glucose utilization).
Renal effects. This is the first report of the renal effects of
Ucn. In contrast with the lack of renal effects observed in
normal sheep, Ucn markedly increased urine volume and
urine sodium and creatinine excretion in HF sheep. These
effects—both dose-dependent and sustained overnight—
occurred despite falls in arterial pressure (and, hence, renal
perfusion pressure) and large reductions in plasma natri-
uretic peptide concentrations. The significant and persistent
decreases in circulating levels of anti-natriuretic/anti-
diuretic factors such AVP, AngII, and aldosterone (and
possibly endothelin-1) are likely to have played a role in
these renal responses. It is also likely that Ucn has effects on
renal hemodynamics, given the major effects on CO and
vascular resistance, and reported vasodilator actions in a
variety of vascular beds (4,8,24,30). Direct tubular actions
may also have occurred given the relative rise in urine
cAMP excretion observed in the present study, and reports
of Ucn expression within the kidney in the rat (5). Increased
glomerular filtration, reflected by the impressive increase in
creatinine clearance, may also have contributed to the
natriuretic/diuretic effect observed in the HF sheep. These
effects were observed notwithstanding the substantial de-
cline in plasma AngII levels that would be expected, under
other circumstances, to result in a decrease in efferent
arteriolar tone and, hence, in both intraglomerular pressure
and glomerular filtration rate. Clearly, the situation is
complex, and the exact mechanisms of these renal effects
need to be investigated further.
In conclusion, this study is the first to investigate the
effects of Ucn in experimental HF. We observed profound
and sustained cardiovascular, hormonal, and renal effects—
including reductions in peripheral resistance, cardiac pre-
load and afterload, and major increases in CO that were
associated with inhibition of a broad spectrum of
vasoconstrictor/volume-retaining factors and impressive
augmentation of natriuresis, diuresis, and glomerular filtra-
tion. While some of these effects were similar to those
observed in normal sheep, some were significantly en-
hanced, for example, falls in CTPR, atrial pressure, PRA,
and plasma aldosterone, and others were directionally op-
posite (MAP and plasma AVP). These data, together with
other physiological actions reported for Ucn (protection of
cardiac myocytes from hypoxic and ischemia/reperfusion
injury, stimulation of natriuretic peptide secretion, and
anti-inflammatory properties), suggest this peptide may
have protective compensatory actions in cardiovascular dis-
ease.
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